Belluscura PLC Expands its Patent Portfolio

RNS Number : 8740A

Tekcapital plc

17 September 2018

 

17 September 2018

Tekcapital plc

("Tekcapital" or the "Company")

Belluscura PLC Expands its Patent Portfolio

Tekcapital plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from university technology, announces that its portfolio company Belluscura plc ("Belluscura") has expanded its patent portfolio.

Belluscura PLC in conjunction with its exclusive research partner Separation Design Group, announced today the recent filing of three patent applications and the receipt of a Notice of Allowance of a fourth application in the fields of respiratory, postoperative recovery, sedation/sleep monitoring and artificial intelligence.

The latest patent application, titled "System and method for improving patient recovery postoperatively," involves the combining of artificial intelligence and deep learning with Belluscura's patented oxygen enrichment and sleep technology to improve patient postoperative recovery and reduce hospital readmission.

Belluscura now owns or exclusively licenses 15 patents and applications in the respiratory, sedation/sleep monitoring and artificial intelligence (AI) fields.

Commenting on the patenting activities, Bob Rauker, CEO of Belluscura, said, "We are very excited about our next generation technology. It is estimated that patient readmissions in the US alone cost Medicare $27bn per year.  Incorporating AI into our leading-edge oxygen enrichment technology opens up additional markets in postoperative recovery beyond the current rapidly growing $1.2bn portable oxygen concentrator market."

Dr. Clifford Gross, Chairman at Tekcapital commented: "We are delighted with Belluscura's reported progress on the development of its intellectual property."

About Belluscura PLC

Belluscura plc is an English company that is focused on improving healthcare and people's lives by developing new and innovative treatment platforms. They license and develop proprietary technologies that can be applied across a range of treatment possibilities. For additional information, please visit www.belluscura.com.

For further information, please contact:

Tekcapital plc Clifford M Gross, Ph.D.	Via Walbrook PR
finnCap Ltd (Nominated Adviser and Joint Broker)	+ 44 (0) 20 7220 0500
Geoff Nash / Max Bullen-Smith (Corporate Finance)
Alice Lane (ECM)
Novum Securities Limited (Joint Broker)	[phone]
Colin Rowbury (Corporate Broking)
Walbrook PR Ltd	[phone]
Paul Cornelius / Sam Allen / Nick Rome		[e-mail]

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital's objective is to create value from investing in new, university-developed intellectual properties. Additionally, using its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a range of IP investment services to make it easy for organisations to find, evaluate, acquire and license university-developed technology. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

LEI: 213800GOJTOV19FIFZ85

This Press Release contains forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Press Release and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Press Release.

 

END

 

 

NRAGMGMLKDMGRZM